Pemetrexed 7 mg/ml solution for infusion

My Account Area

${arrow_up}$ Back to top

Active Ingredient:

pemetrexed disodium

Company:

Ranbaxy (UK) Limited a Sun Pharmaceutical Company See contact details

ATC code:

L01BA04

About Medicine

${medical_services}$

Prescription only medicine

My Account Area

${arrow_down}$

Healthcare Professionals (SmPC) Patient Leaflet (PIL) HCP Med Info

${arrow_left}$

${arrow_right}$

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine.

Last updated on emc: 16 Aug 2023

View or print the patient leaflet as PDF

Below is a text only representation of the Patient Information Leaflet (ePIL).

The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 31750/0188.

Print patient leaflet as text only

Pemetrexed 5 mg/ml,6 mg/ml, 6.5 mg/ml, 7 mg/ml, 7.5 mg/ml, 8 mg/ml, 8.5 mg/ml, 9 mg/ml, 10 mg/ml, 11 mg/ml solution for infusion

PACKAGE LEAFLET: INFORMATION FOR THE USER

Pemetrexed 5 mg/ml solution for infusion

Pemetrexed 6 mg/ml solution for infusion

Pemetrexed 6.5 mg/ml solution for infusion

Pemetrexed 7 mg/ml solution for infusion

Pemetrexed 7.5 mg/ml solution for infusion

Pemetrexed 8 mg/ml solution for infusion

Pemetrexed 8.5 mg/ml solution for infusion

Pemetrexed 9 mg/ml solution for infusion

Pemetrexed 10 mg/ml solution for infusion

Pemetrexed 11 mg/ml solution for infusion

pemetrexed

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

Keep this leaflet. You may need to read it again.
If you have any further questions, please ask your doctor, pharmacist or nurse.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Pemetrexed is and what it is used for
2. What you need to know before you are given Pemetrexed
3. How Pemetrexed will be given
4. Possible side effects
5. How to store Pemetrexed
6. Contents of the pack and other information

1. What Pemetrexed is and what it is used for

Pemetrexed contains the active substance pemetrexed, which belongs to the group of medicines used in the treatment of cancer. It is used:

in combination with cisplatin, another anti-cancer medicine, as treatment for malignant pleural mesothelioma, a form of cancer that affects the lining of the lung, to patients who have not received prior chemotherapy
in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer
as a treatment for patients with lung cancer at an advanced stage if their disease has responded to treatment or it remains largely unchanged after initial chemotherapy
as a treatment for patients with advanced stage of lung cancer whose disease has progressed after other initial chemotherapy has been used.

2. What you need to know before you are given Pemetrexed

You should NOT be given Pemetrexed

if you are allergic to pemetrexed or any of the other ingredients of this medicine (listed in section 6)
if you are breast-feeding; you must discontinue breast-feeding during treatment with Pemetrexed
if you have recently received or are about to receive a vaccine against yellow fever.

Warnings and precautions

Talk to your doctor before you are given Pemetrexed

if you currently have or have previously had problems with your kidneys, as you may not be able to receive Pemetrexed.
Before each infusion you will have samples of your blood taken to see if you have sufficient kidney and liver function and to check that you have enough blood cells to receive Pemetrexed. Your doctor may decide to change the dose or delay treating you depending on your general condition and if your blood cell counts are too low. If you are also receiving cisplatin, your doctor will make sure that you are properly hydrated and receive treatment before and after receiving cisplatin to prevent vomiting.
if you have had or are going to have radiation therapy, as there may be an early or late radiation reaction with Pemetrexed
if you have been recently vaccinated, as this can possibly cause bad effects with Pemetrexed
if you have heart disease or a history of heart disease
if you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you Pemetrexed.

Children and adolescents

This medicine should not be used in children or adolescents, since there is no experience with this medicine in children or adolescents under 18 years of age.

Other medicines and Pemetrexed

Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.

Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor’s prescription (such as ibuprofen). There are many sorts of NSAIDs with different durations of activity. Based on the planned date of your infusion of Pemetrexed and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them. If you are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs.

Pregnancy, breast-feeding and fertility

Pregnancy

If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine. The use of Pemetrexed should be avoided during pregnancy. Your doctor will discuss with you the potential risk of receiving Pemetrexed during pregnancy. Women must use effective contraception during treatment with Pemetrexed.

Breast-feeding

If you are breast-feeding, tell your doctor.

Breast-feeding must be discontinued during treatment with Pemetrexed.

Fertility

Men are advised not to father a child during and up to 6 months following treatment with Pemetrexed and should therefore use effective contraception during treatment with Pemetrexed and for up to 6 months afterwards. If you would like to father a child during the treatment or in the 6 months following receipt of treatment, seek advice from your doctor or pharmacist. You may want to seek counselling on sperm storage before starting your therapy.

Driving and using machines

Pemetrexed may make you feel tired. Be careful when driving a car or using machines.

Pemetrexed contains sodium

Pemetrexed 5 mg/ml contains 407.9 mg (17.7 mmol) sodium (main component of cooking/table salt) per infusion bag. This is equivalent to 20.4 % of the maximum daily dietary intake of sodium for an adult.

Pemetrexed 6 mg/ml contains 418.6 mg (18.2 mmol) sodium (main component of cooking/table salt) per infusion bag. This is equivalent to 20.9 % of the maximum daily dietary intake of sodium for an adult.

Pemetrexed 6.5 mg/ml contains 424.0 mg (18.4 mmol) sodium (main component of cooking/table salt) per infusion bag. This is equivalent to 21.2 % of the maximum daily dietary intake of sodium for an adult.

Pemetrexed 7 mg/ml contains 429.4 mg (18.7 mmol) sodium (main component of cooking/table salt) per infusion bag. This is equivalent to 21.5 % of the maximum daily dietary intake of sodium for an adult.

Pemetrexed 7.5 mg/ml contains 434.8 mg (18.9 mmol) sodium (main component of cooking/table salt) per infusion bag. This is equivalent to 21.7 % of the maximum daily dietary intake of sodium for an adult.

Pemetrexed 8 mg/ml contains 440.1 mg (19.1 mmol) sodium (main component of cooking/table salt) per infusion bag. This is equivalent to 22.0 % of the maximum daily dietary intake of sodium for an adult.

Pemetrexed 8.5 mg/ml contains 445.5 mg (19.4 mmol) sodium (main component of cooking/table salt) per infusion bag. This is equivalent to 22.3 % of the maximum daily dietary intake of sodium for an adult.

Pemetrexed 9 mg/ml contains 450.9 mg (19.6 mmol) sodium (main component of cooking/table salt) per infusion bag. This is equivalent to 22.5 % of the maximum daily dietary intake of sodium for an adult.

Pemetrexed 10 mg/ml contains 461.7 mg (20.1 mmol) sodium (main component of cooking/table salt) per infusion bag. This is equivalent to 23.1 % of the maximum daily dietary intake of sodium for an adult.

Pemetrexed 11 mg/ml contains 472.4 mg (20.5 mmol) sodium (main component of cooking/table salt) per infusion bag. This is equivalent to 23.6 % of the maximum daily dietary intake of sodium for an adult.

3. How Pemetrexed will be given

The recommended dose of Pemetrexed is 500 milligrams for every square meter of your body’s surface area. Your height and weight are measured to work out the surface area of your body. Your doctor will use this body surface area to work out the right dose for you. This dose may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition.

You will always receive Pemetrexed by infusion into one of your veins. The infusion will last approximately 10 minutes.

When using Pemetrexed in combination with cisplatin

the doctor or pharmacist will work out the dose you need based on your height and weight. Cisplatin (75 milligrams for every square meter of your body’s surface area) is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of Pemetrexed has finished. The infusion of cisplatin will last approximately 2 hours.

You should usually receive your infusion once every 3 weeks.

Additional medicines

corticosteroids: your doctor will prescribe you steroid tablets (equivalent to 4 milligram of dexamethasone twice a day) that you will need to take on the day before, on the day of, and the day after Pemetrexed treatment. This medicine is given to you to reduce the frequency and severity of skin reactions that you may experience during your anticancer treatment.
vitamin supplementation: your doctor will prescribe you oral folic acid (vitamin) or a multivitamin containing folic acid (350 to 1000 micrograms) that you must take once a day while you are taking Pemetrexed. You must take at least 5 doses during the seven days before the first dose of Pemetrexed. You must continue taking the folic acid for 21 days after the last dose of Pemetrexed. You will also receive an injection of vitamin B12 (1000 micrograms) in the week before administration of Pemetrexed and then approximately every 9 weeks (corresponding to 3 courses of Pemetrexed treatment). Vitamin B12 and folic acid are given to you to reduce the possible toxic effects of the anticancer treatment.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

You must contact your doctor immediately if you notice any of the following:

fever or infection (common): if you have a temperature of 38ºC or greater, sweating or other signs of infection(since you might have less white blood cells than normal which is very common). Infection (sepsis) may be severe and could lead to death.
if you start feeling chest pain (common) or having a fast heart rate (uncommon).
if you have pain, redness, swelling or sores in your mouth (very common).
allergic reaction: if you develop skin rash (very common) / burning or prickling sensation (common), or fever (common). Rarely, skin reactions may be severe and could lead to death. Contact your doctor if you get a severe rash, or itching, or blistering (Stevens-Johnson Syndrome or Toxic epidermal necrolysis).
if you experience tiredness, feeling faint, becoming easily breathless or if you look pale (since you might have less haemoglobin than normal which is very common).
if you experience bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising (since you might have less platelets than normal which is very common).
if you experience sudden breathlessness, intense chest pain or cough with bloody sputum (uncommon)(may indicate a blood clot in the blood vessels of the lungs).

Serious side effects

Very common (may affect more than 1 in 10 people)

infection
pharyngitis (a sore throat)
low number of neutrophil granulocytes (a type of white blood cell)
low white blood cells
low haemoglobin level
pain, redness, swelling or sores in your mouth
loss of appetite
vomiting
diarrhoea
nausea
skin rash
flaking skin
abnormal blood tests showing reduced functionality of kidneys
fatigue (tiredness).

Common (may affect up to 1 in 10 people)

blood infection
fever with low number of neutrophil granulocytes (a type of white blood cell)
low platelet count
allergic reaction
loss of body fluids
taste change
damage to the motor nerves which may cause muscle weakness and atrophy (wasting) primary in the arms and legs)
damage to the sensory nerves that may cause lost of sensation, burning pain and unsteady gait
dizziness
inflammation or swelling of the conjunctiva (the membrane that lines the eyelids and covers the white of the eye
dry eye
watery eyes
dryness of the conjunctiva (the membrane that lines the eyelids and covers the white of the eye) and cornea (the clear layer in front of the iris and pupil.
swelling of the eyelids
eye disorder with dryness, tearing, irritation, and/or pain
cardiac Failure (Condition that affects the pumping power of your heart muscles)
irregular heart rhythm
indigestion
constipation
abdominal pain
liver: increases in the chemicals in the blood made by the liver
increased skin pigmentation
itchy skin
rash on the body where each mark resembles a bullseye
hair loss
hives
kidney stop working
reduced functionality of kidney
fever
pain
excess fluid in body tissue, causing swelling
chest pain
inflammation and ulceration of the mucous membranes lining the digestive tract.

Uncommon (may affect up to 1 in 100 people)

reduction in the number of red, white blood cells and platelets
stroke
type of stroke when an artery to the brain is blocked
bleeding inside the skull
angina (Chest pain caused by reduced blood flow to the heart)
heart attack
narrowing or blockage of the coronary arteries
abnormal heart rythm
deficient blood distribution to the limbs
blockage in one of the pulmonary arteries in your lungs
inflammation and scarring of the lining of the lungs with breathing problems
passage of bright red blood from the anus
bleeding in the gastrointestinal tract
ruptured bowel
inflammation of the lining of the oesophagus
inflammation of the lining of the large bowel, which may be accompanied by intestinal or rectal bleeding (seen only in combination with cisplatin)
inflammation, edema, erythema, and erosion of the mucosal surface of the esophagus caused by radiation therapy
inflammation of the lung caused by radiation therapy.

Rare (may affect up to 1 in 1,000 people)

destruction of red blood cells
anaphylactic shock (severe allergic reaction)
inflammatory condition of the liver
redness of the skin
skin rash that develops throughout a previously irradiated area.

Very rare (may affect up to 1 of 10 000 people)

infections of skin and soft tissues
Stevens-Johnson syndrome (a type of severe skin and mucous membranes reaction that may be life threatening)
toxic epidermal necrolysis (a type of severe skin reaction that may be life threatening)
autoimmune disorder that results in skin rashes and blistering on the legs, arms, and abdomen
inflammation of the skin characterized by the presence of bullae which are filled with fluid
skin fragility, blisters and erosions and skin scarring
redness, pain and swelling mainly of the lower limbs
inflammation of the skin and fat beneath the skin (pseudocellulitis)
inflammation of the skin (dermatitis)
skin to become inflamed, itchy, red, cracked, and rough
intensely itchy spots.

Not known (frequency cannot be estimated from the available data)

form of diabetes primarily due to pathology of the kidney
disorder of the kidneys involving the death of tubular epithelial cells that form the renal tubules.

You might have any of these symptoms and/or conditions. You must tell your doctor as soon as possible when you start experiencing any of these side effects.

If you are concerned about any side effects, talk to your doctor.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Pemetrexed

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the infusion bag and the outer packaging after EXP. The expiry date refers to the last day of that month.

Store in the original packaging in order to protect from light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Pemetrexed contains

The active substance is pemetrexed (as disodium, heptahydrate).
The other ingredients are sodium chloride, hydrochloric acid, concentrated (for pH adjustment), sodium hydroxide (for pH adjustment) and water for injection.

One 100 ml infusion bag contains 500 mg pemetrexed (equivalent to 551.43 mg pemetrexed disodium and 699.0 mg of pemetrexed disodium heptahydrate).

One 100 ml infusion bag contains 600 mg pemetrexed (equivalent to 661.71 mg pemetrexed disodium and 838.8 mg of pemetrexed disodium heptahydrate).

One 100 ml infusion bag contains 650 mg pemetrexed (equivalent to 716.85 mg pemetrexed disodium and 908.7 mg of pemetrexed disodium heptahydrate).

One 100 ml infusion bag contains 700 mg pemetrexed (equivalent to 772.0 mg pemetrexed disodium and 978.6 mg of pemetrexed disodium heptahydrate).

One 100 ml infusion bag contains 750 mg pemetrexed (equivalent to 827.14 mg pemetrexed disodium and 1048.5 mg of pemetrexed disodium heptahydrate).

One 100 ml infusion bag contains 800 mg pemetrexed (equivalent to 882.28 mg pemetrexed disodium and 1118.4 mg of pemetrexed disodium heptahydrate).

One 100 ml infusion bag contains 850 mg pemetrexed (equivalent to 937.42 mg pemetrexed disodium and 1188.3 mg of pemetrexed disodium heptahydrate).

One 100 ml infusion bag contains 900 mg pemetrexed (equivalent to 992.57 mg pemetrexed disodium and 1258.2 mg of pemetrexed disodium heptahydrate).

One 100 ml infusion bag contains 1000 mg pemetrexed (equivalent to 1102.85 mg pemetrexed disodium and 1398.0 mg of pemetrexed disodium heptahydrate).

One 100 ml infusion bag contains 1100 mg pemetrexed (equivalent to 1213.14 mg pemetrexed disodium and 1537.8 mg of pemetrexed disodium heptahydrate).

What Pemetrexed looks like and contents of the pack

Pemetrexed solution for infusion is a clear colourless to yellow or green-yellow solution, free from visible particulate matter.

Pemetrexed solution for infusion is packed in cartons each holding 1 or 5 single-dose infusion bags of 100 ml.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Sun Pharmaceutical Industries Europe BV
Polarisavenue 87
2132 JH Hoofddorp
The Netherlands

Manufacturer

Sun Pharmaceutical Industries Europe BV
Polarisavenue 87
2132 JH Hoofddorp
The Netherlands

Terapia S.A.
124 Fabricii Street
400632, Cluj-Napoca
Cluj County
Romania

This medicine is authorised in the Member states of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

France: Pemetrexed SUN

Germany: Pemetrexed SUN

Italy: Pemetrexed SUN Pharma

The Netherlands: Pemetrexed SUN

Spain: Pemetrexed SUN

United Kingdom (Northern Ireland): Pemetrexed SUN

This leaflet was last revised in August 2021.